Evaxion Biotech A/S (EVAX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Evaxion A/S (EVAX) Q1 2026 Earnings Call Transcript
Evaxion A/S (EVAX) Q1 2026 Earnings Call Transcript
Evaxion A/S (EVAX) Q4 2025 Earnings Call Transcript
Evaxion A/S (EVAX) Q4 2025 Earnings Call Transcript
Evaxion A/S (EVAX) Q3 2025 Earnings Call Transcript
Evaxion A/S (EVAX) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Birgitte Rono - Interim CEO & Chief Scientific Officer Thomas Schmidt - Chief Financial Officer Conference Call Participants Soumit Roy - JonesTrading Institutional Services, LLC, Research Division Nelson Cox - Lake Street Capital Markets, LLC, Research Division Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Hello, and welcome to the Evaxion Business Update and Third Quarter 2025 Financial Results.
Evaxion Biotech A/S Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Jay Annis Annis Gardner Whiting Capital Advisors, LLC | 30,000 | $111,600 | $109,200 | -$2,400 | -2.15% |
Evaxion Biotech A/S Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SR Swayampakula Ramakanth HC Wainwright & Co. | 9,405.52 | $36,330.76 | $35,646.9 | -$683.86 | -1.88% |
Evaxion Biotech A/S (EVAX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Evaxion Biotech A/S ever had a stock split?
Evaxion Biotech A/S Profile
| Biotechnology Industry | Healthcare Sector | Helen Katrina Tayton-Martin CEO | NASDAQ (CM) Exchange | 29970R303 CUSIP |
| DK Country | 46 Employees | - Last Dividend | 22 Jan 2024 Last Split | 5 Feb 2021 IPO Date |
Overview
Evaxion Biotech A/S represents a forefront clinical-stage biotech entity distinguished by its specialized focus on the development of immunotherapies powered by artificial intelligence. Incorporated in 2008 and having its foundations in Horsholm, Denmark, the company is pioneering in the research and development of novel treatments targeting a range of cancers and infectious diseases. By leveraging the potential of AI, Evaxion Biotech A/S aims to enhance the precision and effectiveness of immunotherapies, paving the way for significant advancements in medical treatments.
Products and Services
Evaxion Biotech A/S boasts an extensive portfolio concentrated on immunotherapies and vaccines, each at varying stages of clinical and pre-clinical development. The following outlines their primary products and services:
- EVX-01: A cutting-edge cancer immunotherapy that is currently undergoing a clinical Phase IIb trial focusing on metastatic melanoma. EVX-01 utilizes the body's immune system to target and destroy cancer cells, representing a potential leap forward in melanoma treatment.
- EVX-02: This is a DNA-based cancer immunotherapy in a Phase 1/2a trial for adjuvant melanoma. By encoding antigens that are specifically expressed on melanoma cells, EVX-02 aims to stimulate an immune response targeted at eradicating these cancer cells.
- EVX-03: As a DNA-based immunotherapy, EVX-03 targets the treatment of various cancers through a patient-specific approach. This strategy holds the promise of tailoring treatments to an individual’s cancer profile, offering a highly personalized therapy option.
- EVX-B1: In the pre-clinical stage, EVX-B1 is a vaccine candidate designed to combat bacterial diseases. Leveraging the body's immune response to bacterial pathogens, this vaccine aims to provide a robust protective shield against multiple bacterial infections.
- EVX-B2: Similar to EVX-B1, this vaccine is also in the pre-clinical phase and is aimed at treating other bacterial diseases not covered by EVX-B1. Through meticulous research and development, EVX-B2 seeks to expand the spectrum of bacterial infections that can be effectively prevented.
- EVX-V1: This pre-clinical stage vaccine targets viral diseases, harnessing the power of the immune system to prevent infections from a range of viruses. With the ongoing threat of viral pandemics, EVX-V1 represents a vital component of Evaxion Biotech A/S’s endeavor to combat viral diseases globally.
